[鲍温样日光性角化病：皮损内注射重组β干扰素治疗]
[Bowenoid actinic keratosis: therapy with intralesional injection of recombinant beta-interferon].
作者信息
Kowalzick L, Mensing H, Weyer U, Kimmig W, Brzoska J
机构信息
Universitäts-Hautklinik Hamburg-Eppendorf.
出版信息
Hautarzt. 1992 Jun;43(6):373-5.
Biopsy-proven bowenoid actinic keratosis located in the pretibial region in each of two elderly women (61 and 81 years) were treated with intralesional injections with a new recombinant beta-interferon. The treatment took the form of intralesional injections three times a week over 3 consecutive weeks. The dose per single injection was 1.5 or 1.0 MU interferon, respectively. Clinical and histological examinations showed a complete response in both patients. Controls up to 18 months showed no relapse. There were no flu-like side-effects. Leukocyte counts decreased by 2700 and 500 cells per microliter during therapy.
两名老年女性（分别为61岁和81岁），其位于胫前区的经活检证实的 Bowen 样光化性角化病，接受了新型重组β干扰素皮损内注射治疗。治疗方式为连续3周每周进行3次皮损内注射。每次注射剂量分别为150万或100万国际单位干扰素。临床和组织学检查显示两名患者均完全缓解。长达18个月的随访未见复发。未出现流感样副作用。治疗期间白细胞计数分别下降了每微升2700个和500个细胞。
Zotero 插件